TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma
pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903)
with supplemental oxygenation.